Three years ago, the physician practice American Health Network was concerned that the boom in employer on-site clinics would hurt its business. So it launched a program aimed at managing the health of employers’ workers. And it has come up with some impressive results.
The Supreme Court will not disturb a lower court ruling that blocks Indiana's effort to strip Medicaid funds from Planned Parenthood because the organization performs abortions.
In the first post on my new blog, The Dose, I explain why the recently released Medicare charge data are meaningless for everyone but uninsured patients.
California residents who choose to buy health insurance through the state exchange being created by the Affordable Care Act may end up paying higher premiums.
Joe Swedish, a career hospital executive, is now two months into his job at the helm of Indianapolis-based WellPoint, the nation’s second-largest health insurer. In his first interview since starting work, Swedish indicated he’s taking his time to learn the people and the culture of the vast organization he now leads.
With premiums for health insurance likely to head north next year as President Obama’s health care reform law fully takes effect, both individuals and employers will pay for more health care out of their own funds and buy less insurance.
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Greenwood officials three years ago approved $8.4 million of incentives for the Elona Biotechnologies project, including the construction loan.
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major developed countries.
Roche Diagnostics Corp. is considering a sale of its blood-glucose meter business, a move that would cast uncertainty over the nearly 1,000 people working for its diabetes business in Indianapolis.
George Bowman, 43, and Traci L. Bowman, 42, are accused of falsifying purchase records and fraudulently filing insurance claims for expensive construction equipment they never purchased.
The future of Indiana’s sprawling health care and life sciences industry might be threatened by an unlikely source: smartphone apps.
Outside observers cast the departures of Lenox Baker, Sheila Burke and Susan Bayh as a positive that will allow new CEO Joseph Swedish to recast the board.
Eli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta is functioning as intended, the Indianapolis-based drugmaker said.
Lenox Baker, Sheila Burke and Susan Bayh resigned from the board effective immediately, Indianapolis-based WellPoint said Monday in a regulatory filing.
Dr. Jay Hess was picked to become the 10th dean in the school of medicine’s 110-year history and the first dean in the past five to come from outside IU.
The state’s medical-device companies are finding that they cannot pass on the new medical-device tax created by Obamacare to their hospital customers, causing them to continue to make cuts and to look to foreign markets for more profitable growth.
Rather than raising prices on private health insurers to make up for inadequate payments from the government, hospitals across the country have been raising prices just because they can, according to a new study.
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues of venture capital, digital health innovations and research university entrepreneurship.
Panel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.
The following is an unedited transcript of the discussion.
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
